Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00397800
Other study ID # CDR0000515982
Secondary ID KRDI-TUM-R-F-015
Status Active, not recruiting
Phase Phase 1/Phase 2
First received November 9, 2006
Last updated August 27, 2012
Start date June 2005
Est. completion date May 2013

Study information

Verified date August 2012
Source Technische Universität München
Contact n/a
Is FDA regulated No
Health authority Germany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving rituximab and chemotherapy together with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of yttrium Y 90 ibritumomab tiuxetan when given together with rituximab, fludarabine, and cyclophosphamide and to see how well they work in treating patients with relapsed B-cell non-Hodgkin's lymphoma.


Description:

OBJECTIVES:

Primary

- Determine the dose-limiting toxicity and maximum tolerated dose of rituximab and yttrium Y 90 (^90Y) ibritumomab tiuxetan when administered with rituximab as radioimmunotherapy after rituximab, fludarabine, and cyclophosphamide in patients with relapsed indolent, mantle cell, or transformed CD20-positive B-cell non-Hodgkin's lymphoma.

Secondary

- Determine the overall survival in patients treated with this regimen.

- Determine time to progression and event-free survival in patients treated with this regimen.

- Determine partial and complete response rates in patients treated with this regimen.

- Determine time to maximal response in patients treated with this regimen.

- Determine response duration in patients treated with this regimen.

- Determine the feasibility of additional antineoplastic treatment following disease relapse after treatment with rituximab and ^90Y ibritumomab tiuxetan in these patients.

OUTLINE: This is a prospective, nonrandomized, multicenter, phase I dose-escalation study of yttrium Y 90 (^90Y) ibritumomab tiuxetan followed by a phase II open-label study.

- Phase I:

- Chemoimmunotherapy: Patients receive rituximab IV on day 1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression. Four weeks after the first day of the last chemoimmunotherapy course, patients receive 1 dose of rituximab IV alone. Patients with disease progression are removed from the study. Patients with stable disease proceed to radioimmunotherapy 8-12 weeks after the first day of the last chemoimmunotherapy course.

- Radioimmunotherapy: Patients receive rituximab IV and an imaging dose of indium In III ibritumomab tiuxetan IV over 10 minutes on day 1. Patients then undergo imaging. If dosimetry is acceptable, patients receive rituximab IV and ^90Y ibritumomab tiuxetan IV over 10 minutes on day 8.

Cohorts of 3-6 patients receive escalating doses of ^90Y ibritumomab tiuxetan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

- Phase II: Patients receive chemoimmunotherapy and radioimmunotherapy as in phase I, at the MTD determined in phase I.

Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for up to 2 years.

PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date May 2013
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender Both
Age group 50 Years to 75 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed CD20-positive B-cell non-Hodgkin's lymphoma (NHL), including any of the following subtypes:

- Indolent NHL, including any of the following:

- Follicular

- Lymphoplasmacytoid

- Marginal zone

- Mantle cell NHL

- Transformed B-cell NHL

- In at least first relapse with an indication for systemic antineoplastic treatment, as defined by the following:

- Local or constitutional (B-) symptoms

- Hypersplenism due to splenic involvement

- Bulky disease (> 7.5 cm in diameter)

- Impending medical problems derived from rapid disease progression within the past 6 months, as defined by an observed or anticipated > 50% increase in the sum of the areas calculated from multiplying the greatest perpendicular diameters of each lesion

- Measurable lesions of lymphoma infiltration

- Medically ineligible for high-dose treatment followed by autologous stem cell support

- Adequate bone marrow cellularity (> 15% of marrow area covered by hematopoiesis)

- No CNS, leptomeningeal, spinal cord, or testes lymphoma involvement

- No lymphoma lesion mandating emergency radiotherapy

- No clinical, cytological, cytogenetic, or histopathologic indication of myelodysplastic syndrome

- If there is bone marrow infiltration detected prior to chemoimmunotherapy, patient must undergo a repeat bone marrow biopsy prior to planned treatment with radioimmunotherapy to verify the level of bone marrow infiltration is < 25%

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy = 3 months

- Absolute neutrophil count > 1,500/mm³

- Platelet count > 150,000/mm³

- Hemoglobin > 9 g/dL

- Creatinine < 1.5 times upper limit of normal (ULN)

- Bilirubin < 2 times ULN

- ALT and AST < 2 times ULN

- Albumin > 2.5 g/dL

- INR < 1.5

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for = 12 months after completion of study treatment

- No concurrent severe and/or uncontrolled medical disease that would preclude study compliance, including any of the following:

- Uncontrolled diabetes

- Congestive heart failure

- Chronic renal disease

- Active uncontrolled infection

- No bleeding risks or disorders, including any of the following:

- CNS abnormalities suggesting an increased susceptibility for hemorrhage, including recent history of stroke as demonstrated by cranial contrast-enhanced CT scan

- Severe arrhythmia or uncontrolled hypertension

- Myocardial infarction within the past 6 months

- Diabetic retinopathy with history of symptomatic hemorrhage

- Known and potentially active gastrointestinal bleeding foci

- Concurrent anticoagulant medication that must be continued even with platelet count < 20,000/mm³ (e.g., following mitral valve replacement, anti-phospholipid syndrome, or recurrent venous thromboembolism)

- Other congenital or acquired hemorrhagic diatheses

- No ongoing autoimmune hemolytic anemia

- No known presence of anti-murine antibody reactivity

- No known hypersensitivity to murine or chimeric antibodies or proteins

- No known HIV infection

- No psychiatric illness that would preclude study requirements

- No other malignant disorder within the past 10 years except basal cell carcinoma of the skin or carcinoma in situ of the cervix

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Recovered from prior therapy

- No more than 4 prior systemic anti-lymphoma regimens (including single-agent rituximab)

- At least 2 months since prior systemic anti-lymphoma treatment (including single-agent rituximab)

- No prior radioimmunotherapy

- No prior autologous or allogeneic hematopoietic stem cell transplantation

- No prior treatment with purine analogues that has not resulted in remission for > 1 year

- No prior anti-CD20 radioimmunoconjugate therapy

- More than 5 years since prior radiotherapy to extensive fields covering lymph node regions on both sides of the diaphragm or > 50% of the spinal column

- More than 4 weeks since prior surgery

- No concurrent oral anticoagulant therapy

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
rituximab

Drug:
cyclophosphamide

fludarabine phosphate

Radiation:
yttrium Y 90 ibritumomab tiuxetan


Locations

Country Name City State
Germany Medizinische Klinik, Klinikum Augsburg Augsburg
Germany Medizinische Klinik III - Universitaetsklinikum Erlangen Erlangen
Germany Universitaetsklinikum Goettingen Goettingen
Germany Universitaetsklinikum Schleswig-Holstein - Campus Luebeck Luebeck
Germany Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg Magdeburg
Germany Universitatsklinik Mainz Mainz
Germany Klinikum Rechts Der Isar - Technische Universitaet Muenchen Munich
Germany LMU-Klinikum Grosshadern Munich
Germany Klinikum der Universitaet Regensburg Regensburg
Germany Universitaetsklinikum Tuebingen Tuebingen
Germany Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm Ulm
Germany Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg Wuerzburg

Sponsors (1)

Lead Sponsor Collaborator
Technische Universität München

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity Yes
Secondary Response No
Secondary Survival No
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT04270266 - Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma N/A
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT01949883 - A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Phase 1
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT04434937 - Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) Phase 2
Completed NCT01855750 - A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Phase 3
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Terminated NCT00775268 - 18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Terminated NCT00014560 - Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Active, not recruiting NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer Phase 1